We have located links that may give you full text access.
Development and Validation of Staging Systems for AA Amyloidosis.
Journal of the American Society of Nephrology : JASN 2024 March 22
BACKGROUND: The kidney is involved in almost 100% of cases of AA amyloidosis, a rare disease caused by persistent inflammation with long overall survival but frequent progression to end-stage kidney failure . Identification of patients with advanced disease at diagnosis is difficult, given the absence of validated staging systems.
METHODS: Newly diagnosed patients with AA amyloidosis from the Pavia (n=233, testing cohort) and Heidelberg (n=243, validation cohort) centers were included in the study. Cut-offs of continuous variables were determined by ROC analysis predicting death or dialysis at 24 months. Prognostic factors included in staging systems were identified by multivariable models in the testing cohort.
RESULTS: Age ≥65 years, estimated glomerular filtration rate (eGFR) <45 mL/min/1.73m2 and elevated natriuretic peptides (type-B natriuretic peptide [BNP] >130 ng/L and/or N-terminal BNP [NT-proBNP] >1000 ng/L) were predictors of overall survival and included in the staging system (all with simplified coefficients 1). Mean 36-months overall survival was lower with higher staging system scores (score 0-1: 92%; score 2: 72%; score 3: 32%). These results were confirmed in the validation cohort. For kidney failure, variables selected to enter in the staging system model were proteinuria >3 g/24h and eGFR <35 mL/min/1.73m2 (both with simplified coefficients 1). The 36-month cumulative incidence of kidney failure was higher with higher staging system scores (score 0: 0%; score 1: 24%; score 2: 51%). Again, similar results were obtained in validation cohort.
CONCLUSIONS: We identified and validated biomarker-based staging systems for overall survival and kidney failure in AA amyloidosis.
METHODS: Newly diagnosed patients with AA amyloidosis from the Pavia (n=233, testing cohort) and Heidelberg (n=243, validation cohort) centers were included in the study. Cut-offs of continuous variables were determined by ROC analysis predicting death or dialysis at 24 months. Prognostic factors included in staging systems were identified by multivariable models in the testing cohort.
RESULTS: Age ≥65 years, estimated glomerular filtration rate (eGFR) <45 mL/min/1.73m2 and elevated natriuretic peptides (type-B natriuretic peptide [BNP] >130 ng/L and/or N-terminal BNP [NT-proBNP] >1000 ng/L) were predictors of overall survival and included in the staging system (all with simplified coefficients 1). Mean 36-months overall survival was lower with higher staging system scores (score 0-1: 92%; score 2: 72%; score 3: 32%). These results were confirmed in the validation cohort. For kidney failure, variables selected to enter in the staging system model were proteinuria >3 g/24h and eGFR <35 mL/min/1.73m2 (both with simplified coefficients 1). The 36-month cumulative incidence of kidney failure was higher with higher staging system scores (score 0: 0%; score 1: 24%; score 2: 51%). Again, similar results were obtained in validation cohort.
CONCLUSIONS: We identified and validated biomarker-based staging systems for overall survival and kidney failure in AA amyloidosis.
Full text links
Related Resources
Trending Papers
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.Diabetologia 2024 April 17
British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.Rheumatology 2024 April 17
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Albumin: a comprehensive review and practical guideline for clinical use.European Journal of Clinical Pharmacology 2024 April 13
Eosinophilic Esophagitis: Clinical Pearls for Primary Care Providers and Gastroenterologists.Mayo Clinic Proceedings 2024 April
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app